Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
The Risk of Novel AKT Inhibition on Lethal Neuroendocrine Prostate Cancer Development
FY 2015-16
Summary
One in every eight men is diagnosed with prostate cancer (PCa), rending this disease the most common cancer affecting Canadian men's health. The primary treatment for locally advanced, recurrent, or metastatic PCa is androgen receptor (AR) pathway inhibition (ARPI). However, despite the most potent ARPI applied to patients, tumours invariably recur and no cure is available. In order to better manage this disease, new therapies targeting on the AKT signalling pathway in prostate cancer cells are being explored under multiple ongoing clinical trials in combination with ARPI. The AKT pathway is frequently over-activated in tumours in promoting cell proliferation and therapy-induced resistance to apoptosis. More importantly, this pathway is further stimulated by ARPI through reciprocal activation mechanisms. Nevertheless, emerging evidence warns that co-targeting AR and AKT pathways increases the risk of PCa to progress into one of the most lethal subtypes of therapy-resistant PCa, called neuroendocrine prostate cancer (NEPC). Our pilot pilot studies further showed that inhibition of AKT and AR decreases the expression and function of the RE-1 Silencing Transcription Factor, allowing PCa cells to gain NEPC phenotypes. This study is designed to decipher the molecular mechanism through which AKT and AR inhibition contributes to NEPC progression. Information obtained from this study is critical as it may direct future drug development for patients with therapy-induced NEPC.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
350042
Name
Chen RuiQi
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The Risk of Novel AKT Inhibition on Lethal Neuroendocrine Prostate Cancer Development
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Castration Resistance; Cellular Biology; Cellular Differentiation; Neuroendocrinology; Novel Therapeutic Target; Prostate Cancer; Signaling Pathways; Therapeutic Effects; Tumors; Ubiquitylation
Abstract
One in every eight men is diagnosed with prostate cancer (PCa), rending this disease the most common cancer affecting Canadian men's health. The primary treatment for locally advanced, recurrent, or metastatic PCa is androgen receptor (AR) pathway inhibition (ARPI). However, despite the most potent ARPI applied to patients, tumours invariably recur and no cure is available. In order to better manage this disease, new therapies targeting on the AKT signalling pathway in prostate cancer cells are being explored under multiple ongoing clinical trials in combination with ARPI. The AKT pathway is frequently over-activated in tumours in promoting cell proliferation and therapy-induced resistance to apoptosis. More importantly, this pathway is further stimulated by ARPI through reciprocal activation mechanisms. Nevertheless, emerging evidence warns that co-targeting AR and AKT pathways increases the risk of PCa to progress into one of the most lethal subtypes of therapy-resistant PCa, called neuroendocrine prostate cancer (NEPC). Our pilot pilot studies further showed that inhibition of AKT and AR decreases the expression and function of the RE-1 Silencing Transcription Factor, allowing PCa cells to gain NEPC phenotypes. This study is designed to decipher the molecular mechanism through which AKT and AR inhibition contributes to NEPC progression. Information obtained from this study is critical as it may direct future drug development for patients with therapy-induced NEPC.
Competitiondate
201512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Chen, RuiQi
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~